TY - JOUR
T1 - Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma
AU - Okamoto, Akinao
AU - Yanada, Masamitsu
AU - Miura, Hiroki
AU - Inaguma, Yoko
AU - Tokuda, Masutaka
AU - Morishima, Satoko
AU - Kanie, Tadaharu
AU - Yamamoto, Yukiya
AU - Mizuta, Shuichi
AU - Akatsuka, Yoshiki
AU - Yoshikawa, Tetsushi
AU - Mizoguchi, Yoshikazu
AU - Nakamura, Shigeo
AU - Okamoto, Masataka
AU - Emi, Nobuhiko
N1 - Publisher Copyright:
© 2015 Japanese Cancer Association.
PY - 2015/11/1
Y1 - 2015/11/1
N2 - It is still a matter of debate whether detection of Epstein-Barr virus (EBV) DNA in pretreatment serum has clinical implications for diffuse large B-cell lymphoma. For this study, we measured EBV DNA load in pretreatment serum from 127 diffuse large B-cell lymphoma patients without any underlying immunodeficiency to evaluate its effects on clinical manifestations and prognosis. Anthracycline-based chemotherapy in combination with rituximab was given as initial therapy for 119 patients (94%). Epstein-Barr virus DNA was detected in 15 patients (12%), who were older (P = 0.005) and tended to be at a more advanced disease stage (P = 0.053). They showed significantly worse progression-free survival (PFS) and overall survival (OS) than other patients (P < 0.001 each). This effect remained significant (P = 0.004 and P = 0.027, respectively) after adjustment for age, lactate dehydrogenase, performance status, stage, and extranodal sites. The status of EBV-encoded small RNA in situ hybridization was known for 123 patients; 6 of 8 positive patients (75%) and 9 of 115 negative patients (8%) had detectable EBV DNA in pretreatment serum. While patients positive for EBV-encoded small RNA had significantly worse PFS and OS than negative patients (P = 0.001 and P = 0.029, respectively), EBV DNA detection in pretreatment serum was associated with poorer PFS and OS even for the 115 patients negative for EBV-encoded small RNA (P < 0.001 each). These findings suggest that EBV DNA detection in pretreatment serum may have an adverse prognostic impact for patients with diffuse large B-cell lymphoma. For this study, we measured Epstein-Barr virus DNA load in pretreatment serum from 127 diffuse large B-cell lymphoma patients to evaluate its effects on clinical manifestations and prognosis. Our findings show that Epstein-Barr virus DNA detection in pretreatment serum may have an adverse prognostic impact.
AB - It is still a matter of debate whether detection of Epstein-Barr virus (EBV) DNA in pretreatment serum has clinical implications for diffuse large B-cell lymphoma. For this study, we measured EBV DNA load in pretreatment serum from 127 diffuse large B-cell lymphoma patients without any underlying immunodeficiency to evaluate its effects on clinical manifestations and prognosis. Anthracycline-based chemotherapy in combination with rituximab was given as initial therapy for 119 patients (94%). Epstein-Barr virus DNA was detected in 15 patients (12%), who were older (P = 0.005) and tended to be at a more advanced disease stage (P = 0.053). They showed significantly worse progression-free survival (PFS) and overall survival (OS) than other patients (P < 0.001 each). This effect remained significant (P = 0.004 and P = 0.027, respectively) after adjustment for age, lactate dehydrogenase, performance status, stage, and extranodal sites. The status of EBV-encoded small RNA in situ hybridization was known for 123 patients; 6 of 8 positive patients (75%) and 9 of 115 negative patients (8%) had detectable EBV DNA in pretreatment serum. While patients positive for EBV-encoded small RNA had significantly worse PFS and OS than negative patients (P = 0.001 and P = 0.029, respectively), EBV DNA detection in pretreatment serum was associated with poorer PFS and OS even for the 115 patients negative for EBV-encoded small RNA (P < 0.001 each). These findings suggest that EBV DNA detection in pretreatment serum may have an adverse prognostic impact for patients with diffuse large B-cell lymphoma. For this study, we measured Epstein-Barr virus DNA load in pretreatment serum from 127 diffuse large B-cell lymphoma patients to evaluate its effects on clinical manifestations and prognosis. Our findings show that Epstein-Barr virus DNA detection in pretreatment serum may have an adverse prognostic impact.
UR - http://www.scopus.com/inward/record.url?scp=84983126707&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84983126707&partnerID=8YFLogxK
U2 - 10.1111/cas.12812
DO - 10.1111/cas.12812
M3 - Article
C2 - 26353084
AN - SCOPUS:84983126707
SN - 1347-9032
VL - 106
SP - 1576
EP - 1581
JO - Cancer science
JF - Cancer science
IS - 11
ER -
